<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS " code="N03A-001" /></DRUG2>
<DESCRIPTION>Notable decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Substantial decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
